Supriya Lifescience Q4 Net Profit Jumps 47% to ₹74.2 Crore Amid 52% Revenue Surge

Market snapshot: Supriya Lifescience delivered a powerful fourth-quarter performance for FY26, characterized by a sharp 52% increase in revenue and a 47% jump in net profit. While margins saw a minor contraction of 142 basis points year-on-year, the absolute growth in EBITDA highlights strong operational scaling.

Data Snapshot

• Revenue: ₹280 Crore (+52.17% YoY)
• Net Profit: ₹74.2 Crore (+47.22% YoY)
• EBITDA: ₹97.6 Crore (+44.38% YoY)
• EBITDA Margin: 35.30% (vs 36.72% YoY)

What's Changed

• Revenue surged from ₹184 Crore to ₹280 Crore, marking a significant acceleration in market share.
• Operational scaling led to a ₹30 Crore absolute increase in EBITDA compared to the previous year.
• EBITDA margins contracted slightly by 142 bps due to product mix shifts and rising operational costs at new sites.

Key Takeaways

• High topline momentum confirms the successful ramp-up of the Module E facility.
• Anesthetic and Vitamin segments remain core drivers, specifically in Latin American and European markets.
• Profitability remains healthy at 26%+ PAT margin despite minor EBITDA compression.

SAHI Perspective

The Q4 results underscore Supriya Lifescience's transition toward its ₹1,000 Crore revenue goal for FY27. The ability to maintain 35%+ EBITDA margins while growing the topline by over 50% reflects deep backward integration and efficient capacity utilization. Investors should note the USFDA clearance received in April 2026 as a major derisking event for regulated market expansion.

Market Implications

The significant revenue beat is likely to trigger upward earnings revisions for FY27. In the pharmaceutical sector, API manufacturers with high backward integration (74%+) like Supriya are gaining pricing power. Capital allocation remains focused on the Ambernath and Patalganga expansions, which are expected to contribute to CDMO revenue streams in the coming quarters.

Trading Signals

Market Bias: Bullish

Revenue growth of 52% significantly outperforms industry averages, and the 47% profit jump provides strong valuation support even with minor margin volatility.

Overweight: API Manufacturing, CDMO, Specialty Chemicals

Trigger Factors:

• Commercial revenue contribution from Ambernath facility in H1 FY27
• USFDA Establishment Inspection Report (EIR) closure
• Export growth rates in regulated North American markets

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian API sector is witnessing a shift towards high-value specialty molecules and backward integration to reduce dependence on Chinese imports. Supriya's focus on niche therapies like anesthetics and contrast media positions it as a high-margin alternative to bulk commodity API makers.

Key Risks to Watch

• Potential for further margin compression if raw material costs or freight expenses spike.
• Regulatory hurdles in upcoming new product filings for the US market.
• Execution risks associated with the large-scale Patalganga expansion.

Recent Developments

On April 22, 2026, Supriya Lifescience received a successful Establishment Inspection Report (EIR) from the USFDA for its Lote facility, following an inspection in February. In March 2026, the company reconstituted its core board committees to strengthen governance ahead of its next growth phase. Management has reiterated their confidence in reaching a ₹1,000 Crore revenue milestone by FY27.

Closing Insight

With strong cash flow generation and successful regulatory clearances, Supriya Lifescience is well-positioned to scale its CDMO business and entrench its leadership in the anesthetic API market.

FAQs

What drove the 52% revenue growth for Supriya Lifescience in Q4?

Growth was primarily driven by the ramp-up of the Module E facility and increased volumes in the anesthetic segment, which contributes over 50% of total revenues. Expansion in Latin American and European markets further supported the topline surge to ₹280 Crore.

Why did EBITDA margins decline despite high revenue growth?

Margins contracted by 142 bps to 35.30% due to a change in the product mix and higher operational expenses related to the commissioning of the Ambernath facility. However, absolute EBITDA grew by 44% to ₹97.6 Crore, indicating strong operating leverage.

How does the recent USFDA EIR impact the company's outlook?

The EIR received on April 22, 2026, signifies a successful inspection of the Lote facility. This allows Supriya to continue supplying high-margin APIs to the US market and facilitates the filing of new Abbreviated New Drug Applications (ANDAs), crucial for its long-term growth strategy.

High Performance Trading with SAHI.